CN113166252A - 全人抗gitr抗体及其制备方法 - Google Patents

全人抗gitr抗体及其制备方法 Download PDF

Info

Publication number
CN113166252A
CN113166252A CN201980079369.7A CN201980079369A CN113166252A CN 113166252 A CN113166252 A CN 113166252A CN 201980079369 A CN201980079369 A CN 201980079369A CN 113166252 A CN113166252 A CN 113166252A
Authority
CN
China
Prior art keywords
antibody
variable region
seq
chain variable
gitr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980079369.7A
Other languages
English (en)
Other versions
CN113166252B (zh
Inventor
戚倩倩
段清
刘礼乐
杨达志
刘虎
马慧
杨欣秀
王冬旭
戴朝晖
王梦莹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaexplorer Ltd
Shanghai Pharmaexplorer Co Ltd
Original Assignee
Pharmaexplorer Ltd
Shanghai Pharmaexplorer Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaexplorer Ltd, Shanghai Pharmaexplorer Co Ltd filed Critical Pharmaexplorer Ltd
Publication of CN113166252A publication Critical patent/CN113166252A/zh
Application granted granted Critical
Publication of CN113166252B publication Critical patent/CN113166252B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

本发明公开了一种靶向GITR的抗体、其制备方法和用途。具体地，本发明公开了一种新的靶向GITR的嵌合抗体或全人源克隆抗体。本发明还公开了制备所述的单克隆抗体的方法。本发明的单克隆抗体能够高特异性地结合GITR抗原，其具有很高的亲和力并且具有显著抗肿瘤等活性。

Description

PCT国内申请，说明书已公开。

Claims (17)

  1. PCT国内申请，权利要求书已公开。
CN201980079369.7A 2018-11-29 2019-11-29 全人抗gitr抗体及其制备方法 Active CN113166252B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811444696.1A CN111234018A (zh) 2018-11-29 2018-11-29 全人抗gitr抗体及其制备方法
CN2018114446961 2018-11-29
PCT/CN2019/122134 WO2020108636A1 (zh) 2018-11-29 2019-11-29 全人抗gitr抗体及其制备方法

Publications (2)

Publication Number Publication Date
CN113166252A true CN113166252A (zh) 2021-07-23
CN113166252B CN113166252B (zh) 2023-04-21

Family

ID=70852699

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811444696.1A Withdrawn CN111234018A (zh) 2018-11-29 2018-11-29 全人抗gitr抗体及其制备方法
CN201980079369.7A Active CN113166252B (zh) 2018-11-29 2019-11-29 全人抗gitr抗体及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811444696.1A Withdrawn CN111234018A (zh) 2018-11-29 2018-11-29 全人抗gitr抗体及其制备方法

Country Status (4)

Country Link
US (1) US20220119541A1 (zh)
EP (1) EP3904384A1 (zh)
CN (2) CN111234018A (zh)
WO (1) WO2020108636A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054638A1 (en) * 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
CN105829343A (zh) * 2013-08-30 2016-08-03 美国安进公司 Gitr抗原结合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
JP2008278814A (ja) * 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
SG172176A1 (en) 2008-12-18 2011-07-28 Univ Erasmus Medical Ct Non-human transgenic animals expressing humanised antibodies and use therof
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2017096276A1 (en) * 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829343A (zh) * 2013-08-30 2016-08-03 美国安进公司 Gitr抗原结合蛋白
WO2016054638A1 (en) * 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3904384A1 (en) 2021-11-03
US20220119541A1 (en) 2022-04-21
CN111234018A (zh) 2020-06-05
CN113166252B (zh) 2023-04-21
WO2020108636A1 (zh) 2020-06-04

Similar Documents

Publication Publication Date Title
WO2020143836A1 (zh) Cd73抗体及其制备方法和应用
CN111153995B (zh) Nkg2a抗体及其制备方法和应用
CN113166257B (zh) Cd47抗体及其制备方法和应用
CN113348180A (zh) Ox40抗体及其制备方法和应用
WO2020011275A1 (zh) 一种sema4d抗体及其制备方法和应用
WO2021213478A1 (zh) 抗人b7-h3的单克隆抗体及其应用
US20220010008A1 (en) Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
CN113166251B (zh) 抗人tim-3单克隆抗体及其应用
CN113166252B (zh) 全人抗gitr抗体及其制备方法
CN113045659B (zh) 抗cd73人源化抗体
US20230212294A1 (en) Anti-b7-h3 antibody and preparation therefor and use thereof
WO2023169583A1 (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
CN114316045A (zh) 抗pd-l1抗体及其用途
CN116333143A (zh) Scube2中和抗体及其医药用途
CN116410313A (zh) Cd30人源化鼠单抗开发
TW202235436A (zh) Ｓｉｇｌｅｃ－１５結合蛋白的製備及其用途
CN115611984A (zh) NKp46抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant